Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club | Medical Devices | Videos
Production & Manufacturing
Process & Production
Return to: PBR Home | Production & Manufacturing | Process & Production

Process & Production

EMA’s CHMP recommends approval for three new cancer drugs By PBR Staff Writer
The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has recommended three cancer drugs for approval.
Production & Manufacturing > Process & Production > News
GSK and Janssen seek European approval for sirukumab in rheumatoid arthritis By PBR Staff Writer
GlaxoSmithKline (GSK) and Janssen-Cilag International have submitted a marketing authorization application (MAA) to the European Medicines Agency (EMA) for the approval of sirukumab to treat moderately to severely active rheumatoid arthritis (RA) in adults.
Production & Manufacturing > Process & Production > News FDA grants orphan drug status to Ovid’s OV101 for genetic neurologic disorder By PBR Staff Writer
Ovid Therapeutics has secured orphan drug designation from the US Food and Drug Administration (FDA) for OV101 to treat Angelman syndrome, a genetic disorder that causes developmental and neurologic disabilities.
Production & Manufacturing > Process & Production > News
See more Process & Production news

Latest Process & Production News and Insight

View all Process & Production news or find news targeted to your interests
Emmaus Life Sciences submits NDA to FDA for sickle cell disease treatment
Emmaus Life Sciences has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) requesting marketing approval for its orally administered pharmaceutical grade L-glutamine (PGLG) treatment for sickle cell disease.
Production & Manufacturing > Process & Production > News
Merck’s Keytruda wins FDA breakthrough therapy status, priority review for first-line NSCLC
By PBR Staff Writer
The US Food and Drug Administration (FDA) has granted breakthrough therapy designation and priority review to Merck’s Keytruda (pembrolizumab) for the first-line treatment of patients with advanced non–small cell lung cancer whose tumors express PD-L1.
Production & Manufacturing > Process & Production > News
Aerie submits NDA to FDA for Rhopressa (netarsudil ophthalmic solution) 0.02%
Aerie Pharmaceuticals has submitted its New Drug Application (NDA) to the US Food and Drug Administration (FDA) for Rhopressa (netarsudil ophthalmic solution) 0.02%.
Production & Manufacturing > Process & Production > News
FDA accepts CCP-07 new drug application for full review
Vernalis and Tris Pharma announced that the US Food and Drug Administration (FDA) has accepted the CCP-07 New Drug Application (NDA) for full review.
Production & Manufacturing > Process & Production > News
FDA grants orphan drug status to Catalyst Pharmaceuticals' Firdapse for myasthenia gravis
The US Food and Drug Administration (FDA) has granted Catalyst Pharmaceuticals orphan drug designation for Firdapse (amifampridine phosphate) for the treatment of myasthenia gravis.
Production & Manufacturing > Process & Production > News
Dynavax says PDUFA date for HEPLISAV-B remains unchanged
The US Food and Drug Administration's (FDA) Center for Biologics Evaluation and Research has cancelled the scheduled November 16, 2016, Vaccines and Related Biological Products Advisory Committee (VRBPAC) meeting to review Dynavax Technologies' Biologics License Application (BLA) for HEPLISAV-B [Hepatitis B Vaccine, Recombinant (Adjuvanted)].
Production & Manufacturing > Process & Production > News
Biogen’s Alzheimer’s drug gets FDA fast-track status
By PBR Staff Writer
The US Food and Drug Administration (FDA) has granted fast track designation to Biogen’s investigational Alzheimer’s disease (AD) treatment aducanumab.
Production & Manufacturing > Process & Production > News
ARIAD completes rolling submission of NDA for Brigatinib to FDA
ARIAD Pharmaceuticals has completed the rolling submission of the New Drug Application (NDA) for its investigational anaplastic lymphoma kinase (ALK) inhibitor, brigatinib, to the U.S. Food and Drug Administration (FDA).
Production & Manufacturing > Process & Production > News
Tonix announces successful end-of-phase 2 meeting with FDA for TNX-102 SL in PTSD
Tonix Pharmaceuticals, which is developing next-generation medicines for fibromyalgia and post-traumatic stress disorder (PTSD), has received the final meeting minutes from the U.S. Food and Drug Administration (FDA) from an End-of-Phase 2/Pre-Phase 3 meeting.
Production & Manufacturing > Process & Production > News
Alexion Pharmaceuticals’ ALXN1007 secures EU orphan drug status
Alexion Pharmaceuticals has secured orphan drug designation from the European Commission for ALXN1007 to treat patients with Graft-Versus-Host Disease (GVHD).
Production & Manufacturing > Process & Production > News
View all Process & Production news or find news targeted to your interests